Ignite Creation Date:
2024-05-05 @ 10:17 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01072890
Status:
COMPLETED
Last Update Posted:
2012-03-28
First Post:
2010-02-16
Brief Title:
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
Sponsor:
University of California Davis
Organization:
University of California Davis
Study Overview
Official Title:
Phase I Study of the Combination of Temsirolimus CCI-779 and Pazopanib GW786034 in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the safety of temsirolimus and pazopanib at different doses Patients who have an advanced cancer that is not felt to benefit from standard treatment or are no longer responding to other treatment will be asked to take part in this study The study hypothesis is that temsirolimus and pazopanib can be administered safely in combination and that combined targeting of the mammalian target of rapamycin mTOR and vascular endothelial growth factor receptor VEGFR signaling pathways will be effective in treating patients with advanced solid tumors
Detailed Description:
Despite encouraging clinical activity reported with single-agent VEGF inhibitors mTOR inhibitors and other novel agents patients rarely achieve complete disease response and ultimately undergo disease progression The limited efficacy of single-target inhibition may be due to numerous overlapping signaling pathways involved in Renal Cell Carcinoma proliferation and growth A strategy of multi-target vertical inhibition of the overlapping aberrant VEGF and mTOR pathways by combination therapy may translate to enhanced efficacy over each single agent alone We hypothesize that temsirolimus and pazopanib can be administered safely in combination and that combined targeting of the mTOR and VEGFR signaling pathways will be effective in treating patients with advanced solid tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UCDCC222 | OTHER | University of California Davis | None |